JETEMA saw the highest growth of 2.99% in patent filings in May and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of JETEMA’s patent filings and grants. Buy the databook here.
JETEMA has been focused on protecting inventions in South Korea(KR) with two publications in Q2 2024
The South Korea(KR) Patent Office dominates the patent filings with nearly 50% of filings. The South Korea(KR), and World Intellectual Property Organization(WIPO) patent Office are among the top ten patent offices where JETEMA is filings its patents..
AbbVie and GSK could be the strongest competitors for JETEMA
In terms of grant share, JETEMA stands in seventh position among its competitors. AbbVie and GSK secured the top positions according to recent patent publication data.
For comprehensive analysis of JETEMA's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.